Share on StockTwits

Equities researchers at Oppenheimer reduced their target price on shares of Curis (NASDAQ:CRIS) from $4.50 to $3.00 in a research report issued on Friday, Analyst Ratings.Net reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 49.25% from the stock’s previous close. The analysts noted that the move was a valuation call.

Separately, analysts at Roth Capital cut their price target on shares of Curis from $10.00 to $9.00 in a research note on Monday, March 24th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.23.

Curis (NASDAQ:CRIS) traded up 3.61% on Friday, hitting $2.01. The stock had a trading volume of 399,186 shares. Curis has a 52 week low of $1.91 and a 52 week high of $4.74. The stock has a 50-day moving average of $2.46 and a 200-day moving average of $2.93. The company’s market cap is $172.8 million.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.06). The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.88 million. During the same quarter last year, the company posted ($0.06) earnings per share. Curis’s revenue was up 42.2% compared to the same quarter last year. Analysts expect that Curis will post $-0.22 EPS for the current fiscal year.

Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.